arrow
T

Taro Shibuki

National Cancer Center Hospital East
H指数:12
被引数:523

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

High AXL Expression and Stromal–Angiogenic Immune Phenotypes in Upper Gastrointestinal Cancers

高AXL表达和基质-血管生成免疫表型在上消化道癌中的研究

2026-11-110
OAAI
Case Report: Discordance between RNA-identified ETV6::RET and clinically reportable DNA profiling in salivary gland secretory carcinoma

病例报告:涎腺分泌性癌中RNA鉴定ETV6::RET与临床可报告的DNA分型之间的不一致

2026-09-280
OA
Relationship between initial dose, dose intensity, and survival in unresectable pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid

不可切除胰腺癌患者接受纳米脂质体伊立替康、氟尿嘧啶和甲酰四氢叶酸治疗后初始剂量、剂量强度与生存率之间的关系

2026-08-110
OAAI
AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC

AI集成多组学平台通过循环肿瘤细胞分析,革新抗转移疗法开发:SCRUM-MONSTAR-CTC

2026-07-270
OAAI
Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer

TP53突变型晚期胆道癌的临床-分子特征及免疫检查点抑制剂疗效增强

2026-05-250
OAAI
SCRUM-Japan MONSTAR3 hematology cohort: a nationwide multi-omics integrated platform for next-generation precision medicine in hematologic malignancies

日本SCRUM-Japan MONSTAR3血液学队列:一种全国性多组学整合平台,用于血液系统恶性肿瘤的下一代精准医学

2026-05-230
OAAI
Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI)

利用液体活检多组学和人工智能(AI)进行分子残留病灶(MRD)与多癌种早期检测(MCED)的临床开发

2026-03-060
OAAI
Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of data from the multicenter NAPOLEON-2 study

术前化疗对纳米脂质体伊立替康联合氟尿嘧啶和甲酰四氢叶酸用于不可切除胰腺癌的影响:一项基于多中心NAPOLEON-2研究数据的回顾性分析

2025-11-180
OA
Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 Study
2025-11-010
PRE
FGFR2-IIIc isoform detection reveals prognostic prevalence and a functional link to mesenchymal transition in gastric and gastroesophageal junction cancer

FGFR2-IIIc亚型检测揭示了在胃癌和胃食管结合部癌中的预后普遍性及其与间质转化的功能联系

2025-10-300
OAAI
Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B)

不可切除性胆道癌老年患者的联合化疗:一项使用倾向性评分匹配分析的回顾性观察研究(JON2104-B)

2025-09-060
OAAI
Multicenter Retrospective Study of Efficacy of Systemic Therapy in Patients with Neuroendocrine Tumor Grade 3 (JOSC-2001)

多中心回顾性研究:系统性疗法在神经内分泌肿瘤3级患者中的疗效(JOSC-2001)

2025-09-010
PRE
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302)

纳米脂质体伊立替康与叶酸辅助氟尿嘧啶在胰腺癌患者中治疗前后炎症标志物的比较:NAPOLEON-2 研究 (NN-2302) 的结果

2025-02-210
OA
Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301)
2025-01-270
OAAI
Efficacy of antibody drug conjugate (ADC) by mRNA expression of targeted genes in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-2

抗体药物偶联物(ADC)在晚期实体瘤中的疗效:基于靶向基因的mRNA表达,SCRUM-Japan MONSTAR-SCREEN-2

2024-09-010
PRE
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel
2024-07-230
OAAI